644 Spam-Free Article(s) Found
Sort:
Date
Filter:
All
Symbol Name Last Close Mkt Cap DailyStocks'
Rating
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Friday’s Close
LLY Eli Lilly and Company $105.71 $113.53B N/A
Article Searches
3 Dividend-Paying Pharma Stocks to Buy Now https://www.fool.com/investing/2019/10/15/3-dividend-paying-pharma-stocks-to-buy-now.aspx?source=iedfolrf0000001 Oct 15, 2019 - These aren't the highest payouts in the industry, but they have the best chance to steadily climb.
Lilly Gets FDA Approval for New Oral Tablets for Migraine http://www.zacks.com/stock/news/563662/lilly-gets-fda-approval-for-new-oral-tablets-for-migraine?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-563662 Oct 14, 2019 - Eli Lilly (LLY) gets FDA approval for lasmiditan oral tablets to treat acute migraine in adults.
Pharma Stock Roundup: NVS' New Eye Drug Gets FDA Nod, NVO, GSK, PFE Sign Deals http://www.zacks.com/stock/news/559573/pharma-stock-roundup-nvs-new-eye-drug-gets-fda-nod-nvo-gsk-pfe-sign-deals?cid=CS-ZC-FT-analyst_blog|stock_roundup-559573 Oct 11, 2019 - FDA approves Novartis' (NVS) Beovu. J&J (JNJ) files sBLA for Stelara. Pfizer (PFE), Novo Nordisk (NVO) and Glaxo (GSK) announce collaboration deals.
3 Big Drug/Biotech Stocks Set to Beat Q3 Earnings Estimates http://www.zacks.com/stock/news/557902/3-big-drug-biotech-stocks-set-to-beat-q3-earnings-estimates?cid=CS-ZC-FT-earnings_esp-557902 Oct 10, 2019 - Here we highlight three bigshot drug/biotech companies, which are expected to deliver positive earnings surprises in Q3.
J&J (JNJ) to Start Q3 Earnings Season for Pharma Sector http://www.zacks.com/stock/news/557845/jj-jnj-to-start-q3-earnings-season-for-pharma-sector?cid=CS-ZC-FT-analyst_blog|earnings_preview-557845 Oct 10, 2019 - J&J's (JNJ) cancer drugs are expected to contribute significantly to third-quarter 2019 earnings. Generic/biosimilar headwinds are expected to hurt Pharma unit's sales.
Gilead (GILD) Files NDA for RA Candidate Filgotinib in Japan http://www.zacks.com/stock/news/556224/gilead-gild-files-nda-for-ra-candidate-filgotinib-in-japan?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-556224 Oct 09, 2019 - Gilead's (GILD) new drug application for its JAK1 inhibitor filgotinib seeks treatment of rheumatoid arthritis in adult patients across Japan.
Thermo Fisher Closes API Site Buyout, Fortifies Pharma Unit http://www.zacks.com/stock/news/553102/thermo-fisher-closes-api-site-buyout-fortifies-pharma-unit?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-553102 Oct 07, 2019 - Following the acquisition closure of GlaxoSmithKline's plant, Thermo Fisher (TMO) will continue to manufacture APIs for the same under a multi-year supply agreement.
Novo Nordisk Focuses on Pipeline Development Amid Competition http://www.zacks.com/stock/news/552953/novo-nordisk-focuses-on-pipeline-development-amid-competition?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-552953 Oct 07, 2019 - Novo Nordisk (NVO) has a strong presence in the Diabetes care market and focuses on the development of its pipeline amid competition.
The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly http://www.zacks.com/stock/news/548879/the-zacks-analyst-blog-highlights-bank-of-america-home-depot-philip-morris-nextera-and-eli-lilly?cid=CS-ZC-FT-press_releases-548879 Oct 04, 2019 - The Zacks Analyst Blog Highlights: Bank of America, Home Depot, Philip Morris, NextEra and Eli Lilly
Top Research Reports for Bank of America, Home Depot & Philip Morris http://www.zacks.com/research-daily/547512/top-research-reports-for-bank-of-america-home-depot-philip-morris?cid=CS-ZC-FT-research_daily-547512 Oct 03, 2019 - Top Research Reports for Bank of America, Home Depot & Philip Morris

Pages: 12345678...65

<<<Page 3>